Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q2 2023
Holdings as of Jun 30, 2023, filed Aug 14, 2023. Long positions only; changes compare share counts with Q1 2023.
- Positions
- 26
- −6 vs. Q1 2023
- Portfolio value
- $889.8M
- +$233.0M (+35.5%) vs. Q1 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| DBVTDBV Technologies S.A. | SPONSORED ADR | 92,687 | $176.1K | <0.1% | 00.0% | Unchanged | History |
| SYRESpyre Therapeutics, Inc. | COM | 2,908,100 | $1.31M | 0.1% | +2,908,100 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 312,553 | $2.81M | 0.3% | 00.0% | Unchanged | History |
| THRDThird Harmonic Bio, Inc. | COM | 993,294 | $4.78M | 0.5% | 00.0% | Unchanged | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 739,661 | $8.83M | 1.0% | 00.0% | Unchanged | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 1,325,000 | $13.6M | 1.5% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 1,400,000 | $14.8M | 1.7% | +195,042+16.2% | Added | History |
| CELCCelcuity Inc. | COM | 1,444,141 | $15.9M | 1.8% | +53,369+3.8% | Added | History |
| ADVMAdverum Biotechnologies, Inc. | COM | 10,000,000 | $15.9M | 1.8% | +5,000,000+100.0% | Added | History |
| IMVTImmunovant, Inc. | COM | 900,000 | $17.1M | 1.9% | −540,999−37.5% | Reduced | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 775,000 | $18.2M | 2.0% | +775,000 | New | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 997,596 | $20.9M | 2.3% | +143,712+16.8% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 631,665 | $21.4M | 2.4% | +135,842+27.4% | Added | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 610,000 | $21.8M | 2.4% | +35,000+6.1% | Added | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 2,025,000 | $22.2M | 2.5% | 00.0% | Unchanged | History |
| CABACabaletta Bio, Inc. | COM | 2,368,186 | $30.6M | 3.4% | +533,186+29.1% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 2,348,272 | $47.9M | 5.4% | +616,907+35.6% | Added | History |
| NUVLNuvalent, Inc. | COM | 1,150,000 | $48.5M | 5.4% | +75,000+7.0% | Added | History |
| PCVXVaxcyte, Inc. | COM | 1,015,000 | $50.7M | 5.7% | +815,000+407.5% | Added | History |
| AMAMAmbrx Biopharma Cayman, Inc. | SPONSORED ADS | 3,175,000 | $52.3M | 5.9% | −1,628,447−33.9% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 2,200,000 | $52.3M | 5.9% | +10,341+0.5% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 5,566,026 | $65.9M | 7.4% | +793,605+16.6% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 1,845,000 | $71.0M | 8.0% | 00.0% | Unchanged | History |
| AKROAkero Therapeutics, Inc. | COM | 1,675,000 | $78.2M | 8.8% | +885,000+112.0% | Added | History |
| VERAVera Therapeutics, Inc. | CL A | 5,450,000 | $87.5M | 9.8% | +2,625,971+93.0% | Added | History |
| MRUSMerus N.V. | COM | 4,000,000 | $105.3M | 11.8% | +1,050,000+35.6% | Added | History |
Sold out since Q1 2023 (8)
Positions held at the end of Q1 2023 that are gone from this filing.
| Security | Class | Shares in Q1 2023 | Value in Q1 2023 | % of portfolio in Q1 2023 | History |
|---|---|---|---|---|---|
| Bellus Health Inc New07987C204 | COM NEW | 6,579,359 | $47.4M | 7.2% | – |
| RXDXPrometheus Biosciences, Inc. | COM | 127,156 | $13.6M | 2.1% | History |
| Avidity Biosciences, Inc.05370A108 | COM | 590,705 | $9.07M | 1.4% | – |
| ENTAEnanta Pharmaceuticals Inc | COM | 217,253 | $8.79M | 1.3% | History |
| ALLKAllakos Inc. | COM | 1,900,000 | $8.46M | 1.3% | History |
| ACRSAclaris Therapeutics, Inc. | COM | 635,000 | $5.14M | 0.8% | History |
| RZLTRezolute, Inc. | COM NEW | 898,267 | $1.72M | 0.3% | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 400,000 | $1.62M | 0.2% | History |